Casdin Capital’s Structure Therapeutics GPCR Stock Holding History

Casdin Capital’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$56.6M	Hold	1,175,000	–	–	4.29%	7
2025 Q4	$81.7M	Sell	1,175,000 -380,000	-24%	-$15.5M	5.08%	6
2025 Q3	$43.5M	Buy	1,555,000 +330,000	+27%	+$6.57M	3.63%	8
2025 Q2	$25.4M	Buy	1,225,000 +525,000	+75%	+$11.5M	2.31%	10
2025 Q1	$12.1M	Hold	700,000	–	–	0.99%	18
2024 Q4	$19M	Hold	700,000	–	–	1.26%	18
2024 Q3	$30.7M	Hold	700,000	–	–	2.05%	12
2024 Q2	$27.5M	Sell	700,000 -416,867	-37%	-$17.1M	2.1%	13
2024 Q1	$47.9M	Buy	1,116,867 +25,000	+2%	+$1.05M	3.56%	9
2023 Q4	$44.5M	Sell	1,091,867 -166,299	-13%	-$9.53M	4.37%	5
2023 Q3	$62M	Buy	1,258,166 +261,149	+26%	+$8.42M	6.86%	4
2023 Q2	$41.4M	Buy	997,017 +320,000	+47%	+$8.97M	3.62%	10
2023 Q1	$16.1M	Buy	+677,017	New	+$15.9M	1.33%	23

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Casdin Capital's GPCR Position: Q1 2026 in Review

Casdin Capital held its Structure Therapeutics (GPCR) position steady in Q1 2026 at 1,175,000 shares worth $56.6M. The position accounts for 4.29% of the portfolio, ranked #7.

Casdin Capital first reported a position in GPCR in Q1 2023 and has held it in 13 quarters since. The position peaked at $81.7M in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

Casdin Capital held 1,175,000 shares of Structure Therapeutics worth $56.6M as of Q1 2026.
Casdin Capital left its Structure Therapeutics share count unchanged in Q1 2026.
Structure Therapeutics made up 4.29% of Casdin Capital's portfolio in Q1 2026, its #7 holding.
Casdin Capital first reported a position in Structure Therapeutics in Q1 2023 and has held it in 13 quarters since.
Casdin Capital's Structure Therapeutics position peaked at $81.7M in Q4 2025.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Casdin Capital's 13F filing for Q1 2026, filed 15 May 2026.